Amyris, Inc. (AMRS) |
| 0.05 0 (0%) 01-16 16:00 |
| Open: | 0.064 |
| High: | 0.0643 |
| Low: | 0.05 |
| Volume: | 46,746,028 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.04 |
| Exchange: | NASDAQ Global Select |
| Industry: | Chemicals - Specialty |
| Sector: | Basic Materials |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 29.71 |
| Resistance 1: | 27.47 |
| Pivot price: | 25.65 |
| Support 1: | 23.85 |
| Support 2: | 19.84 |
| 52w High: | 0.0643 |
| 52w Low: | 0.05 |
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 28 Aug 2025
Amyris - AMRS - Stock Price & News - The Motley Fool
Thu, 24 Apr 2025
AMRS Stock Price, News & Analysis - Stock Titan
Thu, 10 Aug 2023
Synthetic biology pioneer Amyris files for Chapter 11 bankruptcy protection - The Business Journals
Thu, 10 Aug 2023
Amyris: Shareholders Likely To Be Wiped Out In Chapter 11 - Sell (NASDAQ:AMRS) - Seeking Alpha
Wed, 09 Aug 2023
AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION - PR Newswire
Mon, 10 Jul 2023
The past five years for Amyris (NASDAQ:AMRS) investors has not been profitable - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |